Matthew Schissler Net Worth: No Forbes Figure — What SEC Filings Show

Matthew Schissler net worth has no verified figure from Forbes, Bloomberg, or any major financial outlet. That gap is itself the story. Most aggregator sites invent a number. This article does not. Instead, it builds from SEC filings, Wikipedia, and a 2024 federal enforcement order — the only primary sources that actually exist.

Early Life and Background

Matthew Lawrence Schissler was born on June 9, 1971, in the United States. He earned a degree in Biology and Public Policy from St. Mary’s College of Maryland in 1993. That dual focus — science and governance — shaped his later approach to building regulated biotech businesses.

His early career before 2003 is not documented in any primary source this article could locate. Publicly available records do not confirm his employment history prior to founding Cord Blood America. Any specific claims about pre-2003 roles on aggregator sites are unverified and were excluded here.

The Biology and Public Policy combination was prescient. Cord blood banking sits at the intersection of medical science and federal health regulation. His degree gave him a framework that most pure scientists or pure business operators lacked at the time.

Career Overview: A Timeline of Verified Events

Schissler’s career divides into three documented phases: biotech founder (2003–2012), private fund manager (2015–present), and a period of regulatory scrutiny (2017–2024).

2003 — Cord Blood America Founded

Schissler founded Cord Blood America, Inc. (CBAI) in 2003. The company stored umbilical cord blood stem cells for potential future medical use. He served as Chairman and CEO. This is confirmed by Wikipedia and SEC filings.

2007 — Acquisitions Scale the Business

CBAI acquired CorCell Inc., then the fourth-largest cord blood bank in America. The same year, it acquired CureSource, a Charleston storage facility with roughly 340 customers. Both acquisitions are documented by Wikipedia citing contemporaneous press releases.

2010 — International Expansion

CBAI acquired 51% of stellacure GmbH of Hamburg, then Germany’s third-largest cord blood bank. It also took majority ownership of BioCells Argentina. Schissler relocated the company to Las Vegas that year, citing tax climate and trade convention logistics. The Wikipedia entry cites his own public statements on the relocation rationale.

2011 — More Acquisitions; Civic Roles

CBAI acquired Chicago-based Reproductive Genetics Institute and NeoCells. Schissler was named chairman of the Biotech Committee for the Nevada Development Authority. He also joined the board of advisors for the Las Vegas Science Festival and the board of the Las Vegas Natural History Museum.

2012 — Departure from CBAI

Schissler stepped away from Cord Blood America in 2012. Wikipedia confirms the departure year. No press release or Tier 1 source documents the financial terms of his exit or any compensation received.

2015–Present — Private Investment Funds

From 2015 onward, Schissler managed a series of private ‘super value’ funds focused on small to mid-cap public companies. These are privately held. No AUM figure, fund performance data, or investor list appears in any public filing reviewed for this article.

2021 — Work Your Core and Aztec Airways

Schissler founded Work Your Core Investments (WYC), LLC in 2021. WYC targets fitness franchise acquisitions. That same year he joined the board of Aztec Airways in Fort Lauderdale, Florida. Both roles are confirmed by Wikipedia.

2017–2022 — GHS Investments Activity (SEC-Documented)

SEC administrative order 34-100769, filed August 19, 2024, documents a critical period. GHS Investments, LLC — a vehicle in which Schissler held a 33% ownership stake alongside Mark Grober and Sarfraz Hajee — operated from 2017 to 2022 as an unregistered securities dealer.

GHS acquired convertible, variable-rate notes from penny stock issuers. It converted those notes into stock at a discount and sold the resulting shares into the public market. GHS generated millions of dollars in profits across at least 23 issuers. This is not alleged — it is stated in the SEC’s settled administrative order, which Schissler and his co-respondents did not contest.

GHS was ordered to pay $2,030,806 in disgorgement, $221,458.43 in prejudgment interest, and a $173,080.62 civil penalty. Each individual respondent — Schissler included — was ordered to pay a personal $10,000 penalty and to cease and desist from future violations of Section 15(a)(1) of the Exchange Act.

Matthew Schissler Net Worth: Earnings Breakdown

IMPORTANT: No Tier 1 financial outlet has reported a net worth figure for Matthew Schissler. The figures below are structural inferences — not reported facts. They are labeled as such throughout.

Structural Inference — Cord Blood America (2003–2012)

Cord Blood America was a publicly traded company on the OTC markets. Its peak market capitalization and insider share values are accessible through SEC EDGAR filings. However, no source documents what compensation Schissler received as CEO, what his equity stake was worth at exit, or the terms of any departure arrangement. Structural inference: founder equity in a company of CBAI’s scale could range from near-zero (if diluted heavily through equity financing rounds) to several million dollars. Without SEC Form 4 insider-transaction data from that period, a specific figure cannot be responsibly stated.

Structural Inference — GHS Investments (2017–2022)

The SEC’s 2024 order confirms GHS generated millions in profits from convertible note trading across 23+ issuers. Schissler owned one-third of GHS. Applying a one-third share to the documented disgorgement figure of $2,030,806 gives a minimum attributable GHS profit share of roughly $677,000 for Schissler — but this is the recovered amount only, not gross earnings. Total GHS profits were materially higher. One-third of ‘millions’ suggests Schissler’s personal GHS earnings may have reached seven figures over the 2017–2022 period. Label: Structural inference based on SEC order — not a reported net worth figure.

Structural Inference — Private Funds and Board Roles (2015–Present)

No AUM data is public for Schissler’s private investment funds. Board director fees at small-cap public companies (his stated focus) typically range from $10,000–$50,000 annually per SEC proxy disclosures at comparable companies. IIOT-OXYS (ITOX), on whose board Schissler sits as director, is a micro-cap stock. Director compensation there is likely at the lower end of that range. Aggregate annual income from multiple board seats and fund management fees: estimated $50,000–$200,000. Label: Structural inference based on industry benchmarks — not a reported figure.

Overall Net Worth Estimate

Combining documented career phases and applying industry benchmarks — while excluding unverified aggregator claims — yields a responsible estimate range of $1 million to $10 million. The high end assumes successful fund performance and favorable CBAI equity at exit. The low end accounts for the costs of SEC disgorgement, legal fees, personal penalty, and the high-dilution nature of OTC biotech equity. Label: Structural inference — not a reported figure. Actual net worth may differ materially.

Endorsements and Sponsorships

No confirmed, named brand endorsement deals or sponsorship arrangements for Matthew Schissler appear in any primary source reviewed for this article. His public profile is that of a private investor and board director. This income category is listed as unverified.

Real Estate Holdings

SEC filings list Schissler’s mailing address as Las Vegas, Nevada 89123. No specific property transactions were located in public deed records for this article. Aggregator sites make real estate claims that could not be verified against any county assessor record or Tier 1 press source. Those claims are excluded. Label: Real estate holdings unverifiable from available public records.

Current Activities

As of April 2026, public records show Schissler active in three areas. First, he remains a Director of IIOT-OXYS, Inc. (ITOX), a publicly traded micro-cap technology company. GuruFocus tracks his insider status there. Second, he continues operating Work Your Core Investments, his 2021-founded fitness-franchise fund. Third, his personal website promotes advisory and mentorship services for executives at small and mid-cap public companies.

The 2024 SEC cease-and-desist order requires Schissler to avoid future violations of Section 15(a)(1) of the Exchange Act. That order is now part of his permanent regulatory record. It does not bar him from investing or serving on boards — but it constrains the convertible-note trading model that GHS used.

Peer Comparison

The table below compares Schissler to peers in biotech founding and private equity. Only Tier 1 or benchmark figures are used. No figure for Schissler himself appears in any Forbes or Bloomberg peer ranking.

Note: Patrick Soon-Shiong is included only to illustrate the wide range within biotech entrepreneurship. He operates at a fundamentally different scale from Schissler. The anonymous PE benchmark and cord blood sector range are industry standards, not named individuals.

Legacy and Cultural Impact

Schissler entered cord blood banking in 2003 — early, by any measure. The global cord blood banking market was nascent. By 2012, his CBAI had operations in the US, Germany, Argentina, and China. That geographic reach at that early stage was unusual for a small-cap OTC biotech founder.

His 2008 Ernst and Young Entrepreneur of the Year finalist nomination — confirmed by Wikipedia — shows he was recognized at the time as a legitimate builder in the Nevada business community. His civic board roles (Nevada Development Authority, Las Vegas Natural History Museum) further document that community standing.

The GHS chapter complicates that legacy. SEC enforcement, even in a settled case without fraud findings, is a material fact about any investor’s career. Schissler’s public-facing materials do not address GHS. That silence is itself a data point for anyone evaluating his financial history.

Conclusion

Matthew Schissler net worth remains unconfirmed by any major financial outlet. What is known: he founded Cord Blood America and built it into an international operation between 2003 and 2012. What is estimated, with structural inference: his net worth likely sits in the $1 million to $10 million range, based on career stage, documented GHS profits, and small-cap investment norms. What is private: fund AUM, CBAI exit terms, and full GHS gross earnings.

The 2024 SEC enforcement order is the most financially detailed primary document about him in any public record. Every aggregator article ignores it. This article does not.

Readers seeking a precise number will not find one — because none has been published by anyone with the authority to verify it.

Browse our Net Worth category covering estimated wealth and financial milestones.